Eli Lilly and Company
NYSE:LLY ISIN:US5324571083
Eli Lilly and Company (NYSE:LLY). The Group's principal activity is to discover, develop, manufacture and market pharmaceutical-based health care solutions. The pharmaceutical products include: Neuroscience, Endocrine, Anti-infective, Cardiovascular agents, Oncology and Animal health. The Group specializes in research and development, production and marketing of products for the treatment of diabetes worldwide, such as insulin and insulin delivery devices. The Group's pharmaceutical products are distributed through wholesalers that serve physicians, pharmacies, hospitals and other health care professionals. The Group's patents include Zyprexa, Prozac, Permax, Darvon, Humulin, Evista, Humalog, Actos, Humatrope, Ceclor, Vancocin, Keflex, Nebcin , Lorabid, Gemzar, Tylan, Rumensin, Micotil, Surmax, Coban, ReoPro, Xigris, Dobutrex and Axid.
News
A legal dispute with the European Patent Office over the European patent for its lead product candidate surprisingly presents a strong buying opportunity for clinical stage biopharmaceutical company Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR), according to an analysis report (http://nnw.fm/8j0TO) released by Aegis Capital Corp on November 23. As such, Aegis analysts reiterated a 'Buy' rating for the company and proposed a higher stock price target of $41, compared to the $25.28 stock price at the time the report was issued.
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company (NYSE:LLY).
###
3,172 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 3) (Last 30 Days: 22) (Since Published: 3172)
